In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 2, 2007, Pages 317-322

  Song, Joon Young ^a   Kee, Sae Yoon ^a   Hwang, In Sook ^a   Seo, Yu Bin ^a   Jeong, Hye Won ^a   Kim, Woo Joo ^a   Cheong, Hee Jin ^a  

^a Korea University   (South Korea)

Author keywords

A. baumannii; Synergy; Time kill assay

Indexed keywords

CARBAPENEM; COLISTIN; IMIPENEM; RIFAMPICIN; SULBACTAM; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; IN VITRO STUDY; INTENSIVE CARE UNIT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; UNIVERSITY HOSPITAL;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; CARBAPENEMS; COLISTIN; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIFAMPIN; SULBACTAM;

EID: 34547849674     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm136     Document Type: Article

References (19)

1. Ayats J, Corbella X, Ardanuy C et al. Epidemiological significance of cutaneous, pharyngeal, and digestive tract colonization by multiresistant Acinetobacter baumannii in ICU patients. J Hosp Infect 1997; 37: 287-95.
2. Jawad A, Heritage J, Snelling AM et al. Influence of relative humidity and suspending menstrua on survival of Acinetobacter spp. on dry surfaces. J Clin Microbiol 1996; 34: 2881-7.
3. Bou G, Cervero G, Dominguez MA et al. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: High-level carbapenem resistance in A. baumannii is not due solely to the presence of beta-lactamases. J Clin Microbiol 2000; 38: 3299-305.
4. Cisneros JM, Reyes MJ, Pachon J et al. Bacteremia due to Acinetobacter baumannii: Epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996; 22: 1026-32.
5. Choi JY, Park YS, Cho CH et al. Synergic in-vitro activity of imipenem and sulbactam against Acinetobacter baumannii. Clin Microbiol Infect 2004; 10: 1098-101.
6. Kiffer CR, Sampaio JL, Sinto S et al. In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii. Diagn Microbiol Infect Dis 2005; 52: 317-22.
7. Falagas ME, Kasiakou SK. Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333-41.
8. Petrosillo N, Chinello P, Proietti MF et al. Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: Clinical outcome and adverse events. Clin Microbiol Infect 2005; 11: 682-3.
9. Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C et al. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 2004; 48: 4479-81.
10. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Sixth Edition: Approved Standard M7-A6. NCCLS, Wayne, PA, USA, 2003.
11. Giamarellos-Bourboulis EJ, Xirouchaki E, Giamarellou H. Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2001; 40: 117-20.
12. Pankey GA. Tigecycline. J Antimicrob Chemother 2005; 56: 470-80.
13. Montero A, Ariza J, Corbella X et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 2004; 54: 1085-91.
14. Li J, Rayner CR, Nation RL et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006; 50: 2946-50.
15. Li J, Nation RL, Tumidge JD et al. Colistin: The re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006; 6: 589-601.
16. Falagas ME, Kasiakou SK, Kofteridis DP et al. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. Eur J Clin Microbiol Infect Dis 2006; 25: 596-9.
17. Reina R, Estenssoro E, Saenz G et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: A prospective cohort study. Intensive Care Med 2005; 31: 1058-65.
18. Motaouakkil S, Charra B, Hachimi A et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 2006; 53: 274-8.
19. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43 Suppl 2: 49-56.